Literature DB >> 6891650

Pharmacokinetics of free platinum species following rapid, 3-hr and 24-hr infusions of cis-diamminedichloroplatinum (II) and its therapeutic implications.

J B Vermorken, W J van der Vijgh, I Klein, H E Gall, H M Pinedo.   

Abstract

The pharmacokinetics of free platinum species derived from cis-diamminedichloroplatinum (II) (cisplatin) was studied in three patients who received the drug as a single agent for the first time at equal doses (100 mg/m2) but with different infusion times. In rapid, 3-hr and 24-hr infusions, peak levels of free platinum were 8.62, 1.96 and 0.27 microgram Pt/ml respectively; half-lives of disposition calculated 0-30 min after the end of each infusion were 17.4, 22.7 and 26.2 min respectively. Free platinum availability, measured as the area under the curves of the free platinum concentration, was the same for the three modes of administration (290, 321 and 325 micrograms Pt/min/ml-1 respectively). This observation supports the clinical impression that antitumour activity of cisplatin is not dependent on the method of administration.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6891650     DOI: 10.1016/0277-5379(82)90085-2

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  26 in total

1.  Combination chemotherapy of cisplatin and 5-fluorouracil for advanced colorectal adenocarcinoma.

Authors:  N J Petrelli; S Madejewicz; Y Rustum; L Herrera; P J Creaven; J Plager; J Soloman; A Mittelman
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

2.  Cisplatin induces modulation of transferrin receptor during cellular differentiation in vitro.

Authors:  G P Tonini; M T Parodi; R Bologna; P Persici; P Cornaglia-Ferraris
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

3.  Correlation between free platinum AUC and total platinum measurement 24 h after i.v. bolus injection of cisplatin in humans.

Authors:  C Fournier; P Vennin; B Hecquet
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

Review 4.  Anticancer drug pharmacodynamics.

Authors:  G Powis
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

5.  Cell survival in four ovarian carcinoma xenografts following in vitro exposure to melphalan, cisplatin and cis-diammine-1,1-cyclobutane dicarboxylate platinum II (CBDCA,JM8).

Authors:  A C Jones; P A Wilson; G G Steel
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

6.  Disposition and tumour concentrations of platinum in hypoalbuminaemic patients after treatment with cisplatin for cancer of the head and neck.

Authors:  J D Holding; W E Lindup; D A Bowdler; M Z Siodlak; P M Stell
Journal:  Br J Clin Pharmacol       Date:  1991-08       Impact factor: 4.335

7.  Physiological pharmacokinetic modeling of cis-dichlorodiammineplatinum(II) (DDP) in several species.

Authors:  F G King; R L Dedrick; F F Farris
Journal:  J Pharmacokinet Biopharm       Date:  1986-04

8.  Influence of infusion time on unchanged cisplatin disposition in patients with ovarian cancer.

Authors:  P A Reece; I Stafford; M Davy; R Morris; S Freeman
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 9.  Pharmacokinetics of anticancer drugs in children.

Authors:  W R Crom; A M Glynn-Barnhart; J H Rodman; M E Teresi; R E Kavanagh; M L Christensen; M V Relling; W E Evans
Journal:  Clin Pharmacokinet       Date:  1987-03       Impact factor: 6.447

10.  Disposition of total and free cisplatin on two consecutive treatment cycles in patients with ovarian cancer.

Authors:  C Erlichman; S J Soldin; J J Thiessen; J F Sturgeon; S Fine
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.